ReviewVaccines2026
Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation.
Review in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young infants and accounts for substantial morbidity, hospitalization, and mortality worldwide, with the highest burden concentrated in the first months of life, when immunological and anatomical immaturity favors severe disease. Maternal vaccination has emerged as a strategy to bridge this window of vulnerability through the transplacental transfer of neutralizing antibodies. This integrative review synthesizes scientific articles published between 2022 and 2026, including systematic reviews, meta-analyses, narrative reviews, and position statements from national and international scientific societies, addressing the epidemiology, clinical manifestations, diagnosis, mechanism of action, efficacy, safety, and public health impact of maternal RSV immunization. The bivalent prefusion F protein vaccine (RSVpreF; Abrysvo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.